



## Financial Tear Sheet

### Primary IR Contact

Ed Bell  
T +1 206-272-4345  
invest@ctibiopharma.com  
(mailto:invest@ctibiopharma.com)

### Transfer Agent

#### Computershare

Mail:  
Computershare Investor Services  
P.O. Box 43078  
Providence, RI 02940-3078

Overnight Delivery:  
Computershare Investor Services  
250 Royall Street  
Canton, MA 02021  
United States of America

T: 312-588-4187  
F: 312-601-4332  
www.Computershare.com  
(<http://www.computershare.com>)

### Corporate Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma's lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited.

**Stock Performance: CTIC (Nasdaq)**

<b>Exchange</b>	NASDAQ CM (US Dollar)
<b>Price</b>	<b>\$5.12</b>
<b>Change (%)</b>	<span style="color: green;">▲</span> 0.07 (1.39%)
<b>Volume</b>	264,299
<b>52 Week Low</b>	\$2.45
<b>Market Cap</b>	\$292,803,560
<b>Rolling EPS</b>	-0.66
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	57,980,903
Data as of 06/19/18 4:00 p.m. ET	



**Recent Headlines & Events**

Jun 14, 2018 - 7:03 a.m.

CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2354543)

Jun 06, 2018 - 7:01 a.m.

CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference (phoenix.zhtml?c=92775&p=irol-newsArticle&ID=2353463)

May 21, 2018 - 8:38 p.m.

CTI Biopharma Corporate Presentation (<http://phx.corporate-ir.net/external.file?t=2&item=o8hHt16027g9XhJTr8+weNRYaV9bFc2rMd0Q/AXw4zsGF7Ag1q6UQW1oRa+ipSrxisFQ5niiANNZqJoDdmvApa/iBJZ5V79LpNz1bbUQ9wWqyIGzSqAq8c5ZIS8dCMdnlwieeEB4p4fo8QtUarWk9Q==&cb=636638296115429996>)

Date	Title
06/21/18 1:00 p.m. ET	<b>CTI BioPharma Corp at JMP Securities 2018 Life Sciences Conference (phoenix.zhtml?c=92775&amp;p=irol-EventDetails&amp;EventId=5272279)</b>

## Ownership Summary

### Shareholders

	<b>Holders</b>	<b>Value (\$MM)</b>	<b>% O/S</b>	<b>Shares</b>
Institution	99	151.96	67.1	38,888,146
Mutual Fund	37	33.89	14.2	8,240,468
Insider *	7	2.75	1.2	691,405

*\*Insider values reflect direct beneficial ownership.*

### Top Holders

	<b>Shares Held</b>	<b>% O/S</b>	<b>Share Change</b>	<b>Filing Date</b>
BVF Partners L.P.	6,929,690	12.0	-1,666,667	03/31/18
Stonepine Capital Management, LLC	5,141,746	8.9	3,306,908	03/31/18
OrbiMed Advisors, LLC	5,000,000	8.6	0	03/31/18
New Enterprise Associates (NEA)	3,750,000	6.5	3,750,000	03/31/18
Franklin Advisers, Inc.	3,472,300	6.0	3,472,300	03/31/18
The Vanguard Group, Inc.	2,152,864	3.7	1,301,983	03/31/18
Great Point Partners, LLC	1,687,020	2.9	1,687,020	03/31/18
Fidelity Management & Research Company	1,400,000	2.4	1,400,000	03/31/18
NB Public Equity Komplementar ApS	1,356,635	2.3	90,000	12/31/16
Sphera Funds Management Ltd.	833,633	1.4	0	03/31/18

*Data provided by Nasdaq. Minimum 15 minutes delayed.*